刚刚，恒瑞医药三季报来了！营收净利双增

Core Insights - The company reported a revenue of 23.188 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 14.85% [1] - The net profit attributable to shareholders reached 5.751 billion yuan, showing a year-on-year increase of 24.50% [1] - The company has increased its focus on innovation, maintaining a high level of research and development investment, with R&D expenses amounting to 4.945 billion yuan in the first three quarters of 2025 [1]